Biologics Contract Manufacturing Market CAGR To Exceed 8.8%, Due To The Growing Demand For Biologics | Roots Analysis

According to our latest market report "Biologics Contract Manufacturing Market by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035", the global biologics contract manufacturing market size is projected to reach USD 55.0 billion by 2035 from USD USD 23.8 billion in 2025, growing at a CAGR of 8.8% in the forecast period.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/biopharmaceutical-contract-manufacturing-market/request-quote.html

Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this segment, driven by the growing preference for effective and personalized pharmacological interventions. Although biopharmaceuticals have demonstrated the potential to treat a myriad of disease indications, they are generally associated with complex manufacturing protocols. This has compelled many biopharmaceutical developers to outsource various aspect of manufacturing operations to contract service providers. The biologics contract manufacturing market is presently characterized by the presence of both niche, specialty companies, focused on early-stage development and production of biologics (preclinical and / or clinical scales), and one-stop-shops, which have, over time, acquired an extensive range of capabilities in order to cater to the product development and commercialization requirements of sponsors.

Biologics Contract Manufacturing Market Segments
Based on the type of service offered, the market is segmented into API manufacturing and FDF manufacturing
1. The API manufacturing segment led the market for biologics contract manufacturing, capturing the largest revenue share of close to 55% in 2023.
2. The API manufacturing segment is anticipated to show the highest growth potential during the forecast period. It was confirmed that the manufacturing of biopharmaceuticals demand significant capital investments, considering this fact, stakeholders rely on the expertise of CMOs for API production.

Based on the type of biologic manufactured, the market is segmented into Antibodies, Vaccines, Cell Therapies and Other Biologics.

1. The antibodies segment led the market for biologics contract manufacturing, capturing the largest revenue share of more than 35% in 2023.
2. The cell therapies segment is anticipated to show the highest growth potential during the forecast period of over 12% annually. This is attributed to the ability of cell therapies in treating various chronic diseases.

Based on the type of expression system used, the market is segmented into Mammalian Expression System, Microbial Expression System and Other Expression Systems.

1. The mammalian expression segment led the market for biologics contract manufacturing, capturing the largest revenue share of close to 60% in 2023.
2. The mammalian expression system segment is anticipated to show the highest growth potential during the forecast period. Owing to their various benefits, including the ability of mammalian expression systems to effectively recognize the signals for synthesis and processing of eukaryotic proteins essential for biological drugs safety and efficacy.

Based on the scale of operation, the market is segmented into Commercial and Preclinical / Clinical.

1. The commercial segment led the market for biologics contract manufacturing, capturing the largest revenue share of close to 90% in 2023.
2. The preclinical / clinical segment is anticipated to show the highest growth potential during the forecast period. Owing to the fact that majority of the biologic-based therapies are in the preclinical / clinical stage.

Based on the company size, the market is segmented into Small, Mid-sized and Large / Very Large.

1. The large / very large companies segment led the market for biologics contract manufacturing, capturing the largest revenue share of close to 60% in 2023.
2. The small companies segment is anticipated to show the highest growth potential during the forecast period. This is attributed to the fact that biologics contract manufacturing market is highly fragmented, featuring the presence of emerging start-ups.

Based on the leading players, the likely share is captured by BioXcellence, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung BioLogics and WuXi Biologics

1. Lonza is the leading player in terms of revenues generated from biologics contract manufacturing business segment of close to 25% in 2022.
2. It is worth mentioning that the firm offers diverse range of biologics development and manufacturing services, along with fully integrated and scalable mammalian and microbial expression platforms.

Biologics Contract Manufacturing Market Regional Outlook
Based on the key geographical regions, the biologics contract manufacturing market can be segmented into five major regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & North Africa. Led by the US, North America is anticipated to capture the majority share of the biologics contract manufacturing market in 2023. The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the biologics contract manufacturing markets in the region is driven by the ecosystem for manufacturing and restraining the cost of goods associated with manufacturing in Asia-Pacific is highly favorable in terms of producing high-quality products for global markets.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-contract-manufacturing-market/request-sample.html

Key Report Takeaways
1. Currently, more than 305 contract manufacturing organizations (CMOs) are engaged in the production of biologics; over 90% of such players provide FDF manufacturing services
2. Around 70% of the stakeholders operate at all scales of operation to cater to the diverse needs of customers; notably, mammalian cell-based expression systems have emerged as a popular choice among CMOs
3. The competition among service providers that claim to be focused on the niche and upcoming drug classes is fierce; it is primarily influenced by the success of several blockbuster therapies in the recent past
4. In the past decade, a shift in trend has been observed in the biopharmaceutical contract manufacturing industry as more players have set up their manufacturing facilities in developing regions across Asia-Pacific
5. A comprehensive set of company profiles of prominent / emerging players offers valuable insights into their current strategic focus and future initiatives, empowering stakeholders with crucial information
6. Over the last five years, more than 695 deals have been inked by biologics CMOs; most of the collaborations were inked for the manufacturing of vaccines, antibodies and cell therapies
7. In order to maintain a competitive edge and establish themselves as one-stop-shops, players are expanding their existing capabilities and service portfolios; the domain has witnessed over 135 mergers and acquisitions
8. Considering the enormous opportunities associated with biologics contract manufacturing, investors have actively extended funds, amounting to USD 7.5 billion, across more than 90 funding instances in the past eight years
9. Driven by the growing demand, CMOs have made elaborate investments to expand their existing capacities and capabilities, primarily for niche biologics; this trend is most pronounced in the US and China
10. In the past five years, over 215 initiatives have been undertaken by big pharma players; more than 80% of such initiatives were focused on partnerships and expansions
11. We anticipate the demand for biologics to steadily rise at an annualized rate of 7% over the next decade; ADC therapeutics and cell therapies will continue to be the key pockets of growth
12. The global installed biopharmaceutical contract manufacturing capacity is spread across various geographies; notably, large players account for 80% of the total capacity
13. Though existing installed capacity is sufficient to meet the current annual demand for biologics, we anticipate that CMOs are likely to invest in installing incremental capacity to meet the long-term demand
14. Our proprietary total cost of ownership model offers an informed estimate of capital and operational expenses associated with the establishment and maintenance of a contract manufacturing facility, over a span of 20 years
15. With the growing pipeline of the biologics and the increased preference for outsourcing, the biopharmaceutical contract manufacturing services market is anticipated to witness a steady growth in the foreseen future
16. As more developers outsource various aspects of their respective manufacturing operations, we expect the biologics CMOs market to grow at an annualized rate of over 9% in the coming decade
17. The anticipated future opportunity, in terms of annual service revenues, is expected to be well distributed across segments, such as scale of operation, company size, leading players and key geographical regions.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/biopharmaceutical-contract-manufacturing-market/250.html

Biologics Contract Manufacturing Market Key Players
Examples of key companies engaged in biologics contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AcuraBio, AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Celltrion, Cytiva, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Novasep, Olon, Patheon, Piramal Pharma Solutions, Samsung Biologics, Sandoz, Takara Bio, Vetter Pharma, Wuxi Biologics.

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.